Search

Search Constraints

You searched for: Author/Creator Hengstler, Jan

Search Results

1. Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non‐small‐cell lung cancer. Issue 9 (8th April 2014)

2. Allowing pseudoscience into EU risk assessment processes is eroding public trust in science experts and in science as a whole: The bigger picture. (25th September 2016)

3. Comparison of a teratogenic transcriptome-based predictive test based on human embryonic versus inducible pluripotent stem cells. Issue 1 (December 2016)

4. Corrigendum to "Critique of the "Comment" etitled "Pyrethroid exposure: not so harmless after all" by Demeneix et al. (2020) published in the lancet diabetes endocrinology". (1st August 2021)

5. Critique of the "Comment" etitled "Pyrethroid exposure: Not so harmless after all" by Demeneix et al. (2020) published in the lancet diabetes endocrinology. (1st April 2021)

6. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. (1st August 2020)

7. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. (1st October 2020)

8. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. (August 2020)

9. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Issue 13 (17th July 2020)

10. Human exposure to synthetic endocrine disrupting chemicals (S-EDCs) is generally negligible as compared to natural compounds with higher or comparable endocrine activity. How to evaluate the risk of the S-EDCs?. Issue 13 (17th July 2020)